当前位置: X-MOL 学术Br. J. Cancer › 论文详情
Effective delivery of Complex Innovative Design (CID) cancer trials—A consensus statement
British Journal of Cancer ( IF 5.416 ) Pub Date : 2020-01-06 , DOI: 10.1038/s41416-019-0653-9
Sarah P. Blagden; Lucinda Billingham; Louise C. Brown; Sean W. Buckland; Alison M. Cooper; Stephanie Ellis; Wendy Fisher; Helen Hughes; Debbie A. Keatley; Francois M. Maignen; Alex Morozov; Will Navaie; Sarah Pearson; Abeer Shaaban; Kirsty Wydenbach; Pamela R. Kearns

The traditional cancer drug development pathway is increasingly being superseded by trials that address multiple clinical questions. These are collectively termed Complex Innovative Design (CID) trials. CID trials not only assess the safety and toxicity of novel anticancer medicines but also their efficacy in biomarker-selected patients, specific cancer cohorts or in combination with other agents. They can be adapted to include new cohorts and test additional agents within a single protocol. Whilst CID trials can speed up the traditional route to drug licencing, they can be challenging to design, conduct and interpret. The Experimental Cancer Medicine Centres (ECMC) network, funded by the National Institute for Health Research (NIHR), Cancer Research UK (CRUK) and the Health Boards of Wales, Northern Ireland and Scotland, formed a working group with relevant stakeholders from clinical trials units, the pharmaceutical industry, funding bodies, regulators and patients to identify the main challenges of CID trials. The working group generated ten consensus recommendations. These aim to improve the conduct, quality and acceptability of oncology CID trials in clinical research and, importantly, to expedite the process by which effective treatments can reach cancer patients.
更新日期:2020-01-06

 

全部期刊列表>>
化学/材料学中国作者研究精选
Springer Nature 2019高下载量文章和章节
ACS材料视界
自然科研论文编辑服务
中南大学国家杰青杨华明
剑桥大学-
中国科学院大学化学科学学院
材料化学和生物传感方向博士后招聘
课题组网站
X-MOL
北京大学分子工程苏南研究院
华东师范大学分子机器及功能材料
中山大学化学工程与技术学院
试剂库存
天合科研
down
wechat
bug